Last updated: June 27, 2026
Purdue Pharma L.P. sued Actavis Laboratories FL, Inc. in 2015 over allegedly infringing Orange Book patents covering Purdue’s extended-release opioid products (commonly implicated in Purdue’s ER oxycodone patent estate). The case name and docket confirm a patent dispute tied to generic/ANDA entry, but the filing record requested here is not included in the prompt, and the case caption alone is insufficient to produce a complete, accurate litigation summary with specific asserted patents, claim numbers, dates, and outcomes.
What patents were asserted in Purdue Pharma L.P. v. Actavis Laboratories FL, Inc. (1:15-cv-00686)?
Answer: Not determinable from the docket identifier and party caption alone.
Which Orange Book patents were listed as asserted in the complaint?
A litigation summary requires the complaint’s “patents-in-suit” list (Orange Book identifiers and specific patent numbers) and the infringement theories (independent method claims vs. composition or formulation claims).
Were infringement claims directed to product strength, dosage form, or abuse-deterrent features?
Purdue’s ER opioid litigation typically centers on formulation and abuse-deterrent mechanics (for example, tamper-resistant or controlled-release structures) and/or use claims. The asserted scope cannot be verified without the complaint or patent list.
What did Actavis Laboratories FL, Inc. argue in its answer and defenses?
Answer: Not determinable from the prompt.
Did Actavis assert invalidity (35 U.S.C. § 102/103/112) and non-infringement?
A defensible analysis needs the answer content: invalidity grounds, anticipation/obviousness arguments, indefiniteness or written description issues, and claim construction positions.
Did Actavis challenge enforceability or patent ownership?
Purdue’s estate has included assignment chain disputes and inventorship-related issues across related matters. The presence or absence of such defenses in this specific case cannot be confirmed from the docket label alone.
What procedural milestones matter in Purdue v. Actavis (1:15-cv-00686)?
Answer: Not determinable from the prompt.
Was there a Markman (claim construction) hearing?
A full litigation summary must state: the court, the scheduling order, and the claim terms construed.
Were there discovery rulings or summary judgment motions?
Key outcomes often turn on dispositive motions and expert admissibility. Without docket entries, dates and rulings cannot be stated accurately.
Did the case end in a settlement, consent judgment, dismissal, or trial verdict?
The business impact depends on the disposition. A settlement typically drives timing for generic market entry, licensing terms, and any agreed carve-outs.
When does Purdue’s patent exclusivity end versus Actavis’s potential launch date?
Answer: Not determinable from the prompt.
How do patent expiration dates map to generic entry risk?
Exclusive rights depend on the specific asserted patents (utility vs. formulation vs. method-of-use) and whether any are terminally disclaimed, subject to PTA adjustments, or tied to pediatric exclusivity.
Did the case involve a Paragraph IV ANDA (Hatch-Waxman)?
A Paragraph IV filing and the resulting 30-month stay are central to launch timing. The docket ID alone does not provide the ANDA/PIV status.
What is the Orange Book status of Purdue patents relevant to this dispute?
Answer: Not determinable from the prompt.
Which NDA/ANDA reference product was tied to the asserted patents?
Purdue’s ER opioids have multiple NDA reference listed drugs (RLDs) and multiple patent families. Correct Orange Book mapping requires the specific NDA and patent numbers.
How does this litigation affect generic entry risk for Actavis and others?
Answer: Not determinable from the prompt.
Did any settlement agreement restrict launch beyond the standard 180-day exclusivity framework?
Market timing impact requires the settlement terms or the dismissal rationale. Generic competitors often rely on the same patent list and entry triggers.
Are there remaining barriers such as design-around patents or continued assertion of other family members?
Purdue’s estate often includes continuation filings and related method-of-use or formulation patents. Whether additional patents remained asserted in parallel matters cannot be confirmed without the docket and orders.
Who else is involved, and does the outcome align with Purdue’s broader ER oxycodone enforcement strategy?
Answer: Not determinable from the prompt.
Are there parallel cases in the same district or coordinated MDL-like posture?
Purdue has had multiple ER opioid disputes across districts. A docket-based summary needs the related-case links and consolidated scheduling.
Case strength analysis for Purdue vs. Actavis: how strong is the patent estate?
Answer: Not determinable from the prompt.
Claim construction and infringement theory impact
Patent strength in this context is largely outcome-driven by: (1) the court’s constructions, (2) the presence of non-infringement design-around facts, and (3) expert testimony. None are available in the prompt.
Validity risks: anticipation/obviousness and specification support
A credible strength assessment requires the exact claims asserted and the prior art references litigated.
Bottom line: litigation outcome and commercial implications
Answer: Not determinable from the prompt.
Without the docket’s substantive entries, the answer cannot state (i) which patents were asserted, (ii) claim constructions adopted, (iii) whether Purdue prevailed, and (iv) what constraints, if any, apply to Actavis launch timing.
Key Takeaways
- The case caption and docket number alone do not provide the asserted patents, infringement claims, procedural milestones, or disposition needed for a reliable litigation summary.
- A business-grade analysis for Purdue vs. Actavis must be anchored to complaint “patents-in-suit,” claim construction outcomes, and final disposition or settlement terms.
- Generic entry timing cannot be mapped without the ANDA/Paragraph IV status and the specific patent expiration/termination dates tied to the patents actually litigated.
FAQs
- What patents are typically asserted in Purdue ER opioid generic litigation under Hatch-Waxman in 1:15-era filings?
- How does Paragraph IV timing and the 30-month stay affect generic entry in Purdue opioid cases?
- Do claim construction outcomes usually determine infringement in Purdue formulation and abuse-deterrent patent disputes?
- What settlement terms commonly appear in Purdue’s generic counterpart agreements (launch dates, royalties, covenants not to sue)?
- How do continuations and family-member patents extend Purdue’s ER exclusivity beyond the first priority filing?
References
- Purdue Pharma L.P. v. Actavis Laboratories FL, Inc., No. 1:15-cv-00686 (Docket and filings).
